PT  - JOURNAL ARTICLE
AU  - AHMED, B.
AU  - LANDUYT, W.
AU  - GRIFFIOEN, A.W.
AU  - VAN OOSTEROM, A.
AU  - VAN DEN BOGAERT, W.
AU  - LAMBIN, P.
TI  - <em>In Vivo</em> Antitumour Effect of Combretastatin A-4 Phosphate Added to Fractionated Irradiation
DP  - 2006 Jan 01
TA  - Anticancer Research
PG  - 307--310
VI  - 26
IP  - 1A
4099  - http://ar.iiarjournals.org/content/26/1A/307.short
4100  - http://ar.iiarjournals.org/content/26/1A/307.full
SO  - Anticancer Res2006 Jan 01; 26
AB  - Background: The study aimed at evaluating the potential benefit from a combination of fractionated ionising radiation with the vascular-targeting compound combretastatin A-4 phosphate (CA-4-P). Materials and Methods: Syngenic rat rhabdomyosarcoma (R1), growing subcutaneously, was treated at 2 different sizes: either small (2±0.5 cm3) or large (10.94±0.6 cm3). Localised fractionated irradiation of the tumours (5 × 3 Gy) in 5 days was followed 1 day later by an intraperitoneal CA-4-P treatment (25 mg/kg). Results: The combined treatment of only large tumours resulted in a small additional growth delay when compared with radiotherapy only. Conclusion: The present data indicate a size-dependent increase in tumour growth delay from combining fractionated irradiation with CA-4-P. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved